EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables)

9 Months Ended

Sep. 30, 2023

Investments, Debt and Equity Securities [Abstract]

Unrealized Gain (Loss) on Investments

Equity securities for the periods presented were comprised of the following:

Security Type	Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
	(In thousands)
September 30, 2023:
Equity securities - Life Sciences Portfolio	$	28,498	$	21,978	$	(103)	$	50,373
Equity securities - other common stock	19,009		2,675		(7,546)		14,138
Total	$	47,507	$	24,653	$	(7,649)	$	64,511
December 31, 2022:
Equity securities - Life Sciences Portfolio	$	28,498	$	14,815	$	(617)	$	42,696
Equity securities - other common stock	34,885		4		(15,977)		18,912
Total	$	63,383	$	14,819	$	(16,594)	$	61,608

The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the consolidated statements of operations:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Change in fair value of equity securities of public    companies	$	8,187	$	(39,008)	$	7,677	$	(243,106)
Gain on sale of equity securities of public    companies	—		36,397		—		101,102
Net realized and unrealized gain (loss)	$	8,187	$	(2,611)	$	7,677	$	(142,004)